Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a market capitalization of $7.53 million, today announced the initiation ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Stock analysts at StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the ...

Investing.com -- Shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) climbed 5% intra-day Tuesday following the announcement that its H. pylori treatment, Talicia, is now covered by Humana (NYSE ...

Photo: Rollingnews.ie The new European Commission needs to get to grips with over-regulation, particularly around licenses in the biopharma sector, according to Enterprise Minister Peter Burke.